Tesamorelin is a stabilized GHRH analog notable for being the only peptide in its class with FDA approval for a therapeutic indication. Clinical data demonstrates targeted visceral fat reduction, making it unique among GH-axis compounds.
Research Applications
Visceral adipose tissue reduction, HIV-associated lipodystrophy, NASH/liver fat research, and cognitive function studies in aging populations.
Dosage Information (Research Use)
Approved clinical dose: 2mg subcutaneously once daily. Research use only.
Reconstitution & Handling
Reconstitute with provided sterile water. Use promptly — less stable than some other GHRH analogs once reconstituted.
Half-Life & Pharmacokinetics
Approximately 26-38 minutes.
Reported Observations in Literature
Clinical trial data: injection site reactions (most common), arthralgia, peripheral edema, myalgia, and paresthesia.
Key Research References
- Falutz J, et al. “Metabolic effects of a growth hormone-releasing factor in patients with HIV.” N Engl J Med. 2007